Biomerica INC 10-Q quarterly reports

Biomerica, Inc. announced its third-quarter fiscal year 2026 financial results, reporting a 12% decrease in net sales compared to the prior year, primarily due to lower contract manufacturing revenue, while also highlighting progress in new product development and a continued focus on liquidity.

Biomerica reported a significant net sales decline and increased operating losses for Q2 2026, raising substantial doubt about its ability to continue as a going concern despite a one-time tax credit.

Biomerica, Inc. reported a net income of $2,000 for Q1 2026, a significant improvement from a loss in the prior year, primarily driven by a one-time Employee Retention Credit refund, despite a 24% drop in net sales.

Biomerica, Inc. reports a net sales increase of 6% for the nine months ended February 28, 2025, but acknowledges substantial doubt about its ability to continue as a going concern due to insufficient cash and strategic growth objectives.

Biomerica's second quarter results show a slight revenue increase but continued losses, prompting cost-cutting measures and a focus on strategic growth.

Biomerica's Q1 2025 results show a slight revenue increase but are overshadowed by rising costs, a workforce reduction, and concerns about the company's ability to continue as a going concern.

Biomerica's Q3 2024 results show a slight revenue increase year-over-year, driven by non-COVID product lines, while the company continues to focus on the rollout of its inFoods IBS product and the launch of its newly FDA-cleared H. pylori diagnostic test.

Biomerica's Q2 2024 results show a slight revenue increase, driven by food intolerance products and contract manufacturing, while the company continues to focus on the launch of its inFoods IBS product and a new H. Pylori test.